Cargando…
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
PURPOSE: The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a receptor over-expressed in ovarian cancer, but largely absent from normal tissue. METHODS:...
Autores principales: | Farrell, Colm, Schweizer, Charles, Wustner, Jason, Weil, Susan, Namiki, Masayuki, Nakano, Tomohisa, Nakai, Kenya, Phillips, Martin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485533/ https://www.ncbi.nlm.nih.gov/pubmed/22955257 http://dx.doi.org/10.1007/s00280-012-1959-y |
Ejemplares similares
-
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
por: Sasaki, Yasutsuna, et al.
Publicado: (2014) -
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015) -
Profile of farletuzumab and its potential in the treatment of solid tumors
por: Sato, Seiya, et al.
Publicado: (2016) -
Evaluation of therapeutic efficacy of (211)At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
por: Palm, Stig, et al.
Publicado: (2020) -
Improved Intraoperative Detection of Ovarian Cancer
by Folate Receptor Alpha Targeted Dual-Modality Imaging
por: Hekman, Marlène C. H., et al.
Publicado: (2017)